Home > Haematology > ASH 2020 > Immune Thrombocytopenia > First-in-class antibody sutimlimab selectively inhibits classical complement pathway

First-in-class antibody sutimlimab selectively inhibits classical complement pathway

Presented By
Dr Catherine Broome, MedStar Georgetown University Hospital, Washington DC, USA
Conference
ASH 2020
Trial
Phase 1
Interim results of an ongoing phase 1b trial with sutimlimab provided additional evidence that the complement pathway plays an important role in immune thrombocytopenia (ITP). A rapid and durable response was elicited and maintained, with an acceptable safety profile [1]. Some patients with ITP display partial response or no response to currently approved treatment protocols. Dr Catherine Broome (MedStar Georgetown University Hospital, Washington DC, USA) and colleagues hypothesised that a primary mechanism of thrombocytopenia in a subset of patients with ITP is classical complement pathway-dependent and that inhibition with sutimlimab would improve thrombocytopenia. Sutimlimab is a first-in-class humanised monoclonal antibody that selectively inhibits activation of the complement pathway by binding to complement protein 1 (C1). An open-label phase 1b study (NCT...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on